Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

NCT01646671 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertension

Interventions

DRUG: LCZ696
DRUG: LCZ696
DRUG: LCZ696

Sponsor

Novartis Pharmaceuticals